Potassium channel gene associations with joint processing speed and white matter impairments in schizophrenia.

Patients with schizophrenia show decreased processing speed on neuropsychological testing and decreased white matter integrity as measured by diffusion tensor imaging, two traits shown to be both heritable and genetically associated indicating that there may be genes that influence both traits as well as schizophrenia disease risk. The potassium channel gene family is a reasonable candidate to harbor such a gene given the prominent role potassium channels play in the central nervous system in signal transduction, particularly in myelinated axons. We genotyped members of the large potassium channel gene family focusing on putatively functional single nucleotide polymorphisms (SNPs) in a population of 363 controls, 194 patients with schizophrenia spectrum disorder (SSD) and 28 patients with affective disorders with psychotic features who completed imaging and neuropsychological testing. We then performed three association analyses using three phenotypes - processing speed, whole-brain white matter fractional anisotropy (FA) and schizophrenia spectrum diagnosis. We extracted SNPs showing an association at a nominal P value of <0.05 with all three phenotypes in the expected direction: decreased processing speed, decreased FA and increased risk of SSD. A single SNP, rs8234, in the 3' untranslated region of voltage-gated potassium channel subfamily Q member 1 (KCNQ1) was identified. Rs8234 has been shown to affect KCNQ1 expression levels, and KCNQ1 levels have been shown to affect neuronal action potentials. This exploratory analysis provides preliminary data suggesting that KCNQ1 may contribute to the shared risk for diminished processing speed, diminished white mater integrity and increased risk of schizophrenia.

Differential methylation of the TRPA1 promoter in pain sensitivity.

Chronic pain is a global public health problem, but the underlying molecular mechanisms are not fully understood. Here we examine genome-wide DNA methylation, first in 50 identical twins discordant for heat pain sensitivity and then in 50 further unrelated individuals. Whole-blood DNA methylation was characterized at 5.2 million loci by MeDIP sequencing and assessed longitudinally to identify differentially methylated regions associated with high or low pain sensitivity (pain DMRs). Nine meta-analysis pain DMRs show robust evidence for association (false discovery rate 5%) with the strongest signal in the pain gene TRPA1 (P=1.2 × 10(-13)). Several pain DMRs show longitudinal stability consistent with susceptibility effects, have similar methylation levels in the brain and altered expression in the skin. Our approach identifies epigenetic changes in both novel and established candidate genes that provide molecular insights into pain and may generalize to other complex traits.

Ethionine carcinogenesis in CD-1, BALB/c and C3H mice.

In two separate in vivo studies, ethionine was evaluated for carcinogenic activity in mice. In the first study, DL-ethionine was fed in a chow diet at 0 (controls), 0.1 (low dose, LD) and 0.25% (high dose, HD) concentrations to the following groups of mice (30 animals/group): Swiss Webster CD-1 females, BALB/c males, and C3H/HeN males and females. Because of severe toxicity, BALB/c females were fed 0.05% (LD) and 0.1% (HD) ethionine. The Swiss and BALB/c mice were maintained on their respective diets for up to 105 weeks before killing whereas the C3H mice were killed at 68 weeks because of the high spontaneous incidence of liver tumors in this strain. The percentages of animals at risk (surviving the time to the first liver tumor recorded in each sex and strain) that bore liver tumors were as follows: Swiss female control, 0% (0/29), Swiss female LD, 87% (20/23); Swiss female HD, 89% (16/18); C3H male controls, 35% (8/23); C3H male LD, 55% (16/29); C3H male HD, 58% (15/26); C3H female controls, 5% (1/20); C3H female LD, 60% (12/20); C3H female HD, 92% (12/13); BALB/c male controls, 4% (1/23); BALB/c male LD, 8% (2/24); BALB/c male HD, 31% (5/16); BALB/c female controls, 0% (0/30); BALB/c female LD, 52% (14/27); and BALB/c female HD, 92% (12/13). The female mice were more responsive than the males in developing liver tumors. The results of the feeding study are compared with those obtained in a second study in which C3H female mice were intubated with 0, 150 or 500 mg DL-ethionine/kg body wt three times per week for 30 weeks and killed at 2 years. Only the LD mice showed a significantly increased incidence of liver tumors (20/39) as compared to controls (12/41) or HD mice (7/37) in the latter study. The hepatic levels of the major ethionine metabolite and methylase inhibitor, S-adenosylethionine (AdoEt), as well as of the endogenous methyl group donor, S-adenosylmethionine (AdoMet) were determined in Swiss female mice fed either 0.1 or 0.3% in the diet for 1-6 weeks. Hepatic AdoEt levels ranged from 37 to 80 micrograms/g liver in the LD animals and from 61 to 203 micrograms/g liver in the HD group; levels of the endogenous metabolite AdoMet correspondingly dropped to 65% of the normal levels. The present results (i) extend to different strains and to both sexes previous observations demonstrating the hepatocarcinogenic activity of ethionine in mice; and (ii) indicate that as in the rat such activity may be exerted through the formation of AdoEt.

Angiotensin II receptors and prolactin release in pituitary lactotrophs.

Logical properties of angiotensin II receptors in the rat adenohypophysis were analyzed in cultured rat pituitary cells incubated with angiotensin II and known stimuli of pituitary hormone secretion. PRL release during incubation for 3 h with 3 nM angiotensin II was consistently increased by 68 +/- 5%, comparable with that elicited by TRH (63.1 +/- 4%). The ED50 of 0.5 nM for PRL release by angiotensin II was significantly lower than that of TRH (2.9 nM) in the same cell cultures. The antagonist analog [Sar1,Ala8]angiotensin II prevented the angiotensin-induced rise in PRL production but not that evoked by TRH, whereas dopamine and SRIF inhibited basal, angiotensin, and TRH-stimulated PRL release. Angiotensin II also caused a small increase in ACTH release but had no effect on the release of LH, TSH, and GH. Angiotensin II binding and PRL release were measured in partially purified lactotrophs prepared by elutriation, by which the initial cell suspension was separated into seven fractions. Most of the lactotrophs were present in the two fractions eluted at flow rates of 15.7 and 19.8 ml/min, as indicated by their immunoreactive PRL content. The 2.5- to 3.2-fold enrichment of lactotrophs was accompanied by a 2- to 3.5-fold increase in angiotensin II receptor concentration, with no change in binding affinity (Ka = 3.5 x 10(9) M-1). In the same fractions, angiotensin II-induced PRL release was similarly increased by 1.6- to 3.5-fold above basal, compared with values of less than 1 in the initial cell suspension and other fractions. The preferential location of angiotensin II receptors in the lactotroph-containing fractions and the close correlation between angiotensin II binding sites and stimulation of PRL release indicate the functional importance of the pituitary angiotensin II receptor sites. These findings also suggest that angiotensin II could contribute to the physiological regulation of PRL secretion.

Hepatic levels of S-adenosylethionine and S-adenosylmethionine in rats and hamsters during subchronic feeding of DL-ethionine.

The levels of S-adenosylethionine (AdoEt) and of S-adenosylmethionine (AdoMet) in the livers of weanling male rats and male and female hamsters fed ethionine for 1-6 weeks were determined. Ethionine was fed at levels of 0, 0.1, and 0.3% in the diet, and the animals were sacrificed after 0, 1, 3 and 6 weeks of treatment. In both species the hepatic contents of AdoEt were dependent upon the level of ethionine in the diet. For the 6-week experimental period the hepatic levels of AdoEt average 81 microgram/g liver in male hamsters fed 0.1% ethionine in the diet and 160 microgram/g in those fed 0.3% ethionine; the corresponding AdoEt levels in female hamsters were 104 and 191 microgram/g liver, respectively. No marked shifts in hepatic AdoEt levels were seen in either male or female hamsters although a gradual rise in hepatic AdoEt from 145 to 233 microgram/g was noted in the female hamsters receiving 0.3% ethionine in the diet for 1-6 weeks. AdoEt levels in the livers of rats fed 0.3% ethionine were quite variable with values of 123, 305 and 127 microgram/g liver noted at weeks 1, 3 and 6 respectively. In rats fed the 0.1% ethionine diet the liver AdoEt levels dropped from 103 to 61 microgram/g from weeks 1 to 6, In animals fed the ethionine-free diet, the hepatic contents of AdoMet were relatively constant throughout the 6-week experimental period, with average values of 25, 17, and 29 microgram/g liver respectively in the male rats, male hamsters and female hamsters. Chronic ethionine administration always suppressed hepatic AdoMet levels. This suppression was generally greater in animals fed the 0.1% ethionine than in those fed the 0.3% ethionine diet. Thus, the average hepatic AdoMet level in rats, male hamsters and female hamsters receiving the 0.1% ethionine diet for 3-6 weeks were 32, 18, and 45% respectively, of the corresponding AdoMet levels in control animals: however, the corresponding AdoMet levels in animals receiving the 0.3% ethionine diet were 66, 42, and 62% of the respective control values. Feeding 0.1% ethionine to male hamsters led to exceedingly low levels of liver AdoMet (1.4-2.9 microgram/g). No direct correlations could be made between the effects of ethionine feeding on the hepatic AdoEt and AdoMet levels in rats and hamsters and the previously reported differences in carcinogenicity by ethionine in these species.